Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
about
Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trialsBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progressionBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaThe Regulation of Matrix Metalloproteinase Expression and the Role of Discoidin Domain Receptor 1/2 Signalling in Zoledronate-treated PC3 Cells.Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.Bone-targeting agents in prostate cancer.Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.HIF targets in bone remodeling and metastatic disease.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.The Globalization of Cooperative Groups.The STAMPEDE trial: paradigm-changing data through innovative trial design.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal OestradiolRisk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.SEOM Clinical Guideline for bone metastases from solid tumours (2016).Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.Management of metastatic hormone-sensitive prostate cancer.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Optimal sequence of bone target drugs in metastatic prostatic cancer.A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [(18)F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.Prostate cancer: Developing novel approaches to castration-sensitive disease.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.Chemotherapy for metastatic castration-sensitive prostate cancer.Therapeutic management of bone metastasis in prostate cancer: an update.Biochemical Changes in the Niche Following Tumor Cell Invasion.The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.Bisphosphonates for advanced prostate cancer.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Evaluation and management of skeletal disease in cancer care.A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients.Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.[Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
P2860
Q26861586-8E979740-637B-45E4-AFF4-B43C58AEA9F3Q27021268-F56318A0-3BA7-4824-A0C7-0F11088D7692Q28068956-6367020D-8F3C-4C4C-93DA-E8CF68897424Q28076686-47BF3141-9DB4-4094-B2AC-5CCB6EEF77F0Q28081996-BF932C63-D1B0-486A-AE39-9237AD0476C9Q30664167-58AE5ED1-0D84-4EE5-B38F-76F612B89020Q30852837-AEB90EA9-83C2-4383-9F6C-E99AFF2A300CQ33864723-12BCFFEC-1E5E-4C58-83DA-3440F4248FFBQ35087364-3E626210-56B6-4152-BCA2-9072DC477A59Q35554344-9F392982-BC9A-49B1-BC68-02AD545F1A00Q35879087-87C78ABA-6193-493F-89C5-04359A6BD856Q36119749-EAF7D3E6-B8A9-4C6A-A4C8-8AF49BD6C312Q36163344-C69513E2-1770-4175-A95C-B3C0F9692E5AQ36707077-D149F4FC-4660-4755-9991-CEC0286858A6Q36861650-9AF572B5-1B94-4BE9-88D1-03C312B89AA9Q37430019-B31DF64D-E1FD-466A-81C3-AED2A0D03909Q37475161-5F04D89B-6A38-4655-9207-D9F77D7C5008Q38252425-FE963349-6554-462B-8D77-D5127F4BECE7Q38353828-041D9B4A-6485-4BAA-8AE2-A903239681D9Q38353835-E5611603-AAB6-40E8-8598-53C1445FF7D6Q38374417-1FF12D43-905E-40EE-8306-5EE2F699537BQ38526456-2983B9A0-0CBA-49A0-B7C6-BB6DBED531AFQ38746311-9CBCD115-5D99-4DB8-95FC-0AA3BF9E2972Q38801270-7A4F3BD9-8F31-4127-9D3A-F98C34376A1EQ38803264-97F05CF3-525A-4714-8A65-37417A1AFC85Q38845259-3859B19D-D1F5-4C20-9963-978659ABF4E3Q38877513-CE4F87CB-D2DA-46D0-BFF9-1CEC24DC0A91Q38964037-94D372D4-4AF9-4B9C-AE07-F4AFB7604755Q39041143-484B3563-2133-4F88-8F65-52C3D6ED2179Q42575268-FC100E98-933C-457A-B7CA-86EB7E42E638Q47248454-0B762C24-147F-4BA1-AE87-1F7864AD22EEQ48110513-B9366B39-237D-42B1-8897-87B390C6B2F8Q50070694-9AAFC536-301C-40DE-B053-DF81D9D45340Q50229125-41712EFF-5F30-4912-9D99-809B23048FDFQ50512926-2F9BEC36-6874-4AA4-9916-127DE0096B6BQ51283625-8E045059-8B03-4643-AE95-1F5DC3478CA0Q52649233-4C47A221-855F-41FC-ADD6-5E8BE13D4D8AQ52857137-C6B0FE89-5603-4B67-A31B-BDDE9E3DA6B2Q53773544-B3DADAFB-2566-4312-B7FC-F42360D9B457Q53786874-75AF71B6-B0B5-4C0C-8158-EAB6B58D992B
P2860
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized controlled trial of ...... lts of CALGB 90202 (alliance).
@en
Randomized controlled trial of ...... stases: results of CALGB 90202
@nl
type
label
Randomized controlled trial of ...... lts of CALGB 90202 (alliance).
@en
Randomized controlled trial of ...... stases: results of CALGB 90202
@nl
prefLabel
Randomized controlled trial of ...... lts of CALGB 90202 (alliance).
@en
Randomized controlled trial of ...... stases: results of CALGB 90202
@nl
P2093
P2860
P356
P1476
Randomized controlled trial of ...... lts of CALGB 90202 (alliance).
@en
P2093
Arif Hussain
Ben Sanford
Charles J Ryan
Eric J Small
J Paul Monk
Matthew R Smith
Michael Morris
Nicholas Vogelzang
Nirmala Bhoopalam
P2860
P304
P356
10.1200/JCO.2013.51.6500
P407
P577
2014-03-03T00:00:00Z